Clinical Research Directory
Browse clinical research sites, groups, and studies.
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
Sponsor: Ono Pharmaceutical Co. Ltd
Summary
This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients with metastatic pancreatic cancer as first-line treatment
Official title: A PhaseⅠStudy to Examine Tolerability and Safety of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and Safety of ONO-7475 in Combination With GnP in Patients With Metastatic Pancreatic Cancer as First-line Treatment
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
87
Start Date
2023-12-06
Completion Date
2028-03-31
Last Updated
2025-04-18
Healthy Volunteers
No
Conditions
Interventions
ONO-7475
Specified dose on specified days
ONO-4538
Specified dose on specified days
Nab-paclitaxel
Specified dose on specified days
Gemcitabine
Specified dose on specified days
Locations (9)
Aichi Cancer Center
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, Japan
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
Osaka International Cancer Institute
Osaka, Osaka, Japan
Seirei Hamamatsu General Hospital
Hamamatsu, Shizuoka, Japan
Juntendo University Hpspital
Bunkyo-ku, Tokyo, Japan
The University of Tokyo Hospital
Bunkyo-ku, Tokyo, Japan
The Cancer Institute Hospital Of JFCR
Koto-Ku, Tokyo, Japan